Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial - Wikidata - wikimedia - TriplyDB

Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial

Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial

http://www.wikidata.org/entity/Q34662112

about

Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration A longitudinal follow-up study of saffron supplementation in early age-related macular degeneration: sustained benefits to central retinal function Geographic atrophy in patients with advanced dry age-related macular degeneration: current challenges and future prospects Nitroxide pharmaceutical development for age-related degeneration and disease Current therapeutic developments in atrophic age-related macular degeneration Age-Related Macular Degeneration: Advances in Management and Diagnosis Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration Update on current and future novel therapies for dry age-related macular degeneration.Dry age-related macular degeneration: A currently unmet clinical need.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.Clinical characteristics and current treatment of age-related macular degeneration.670-nm light treatment reduces complement propagation following retinal degeneration.Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial.Apigenin Attenuates Oxidative Injury in ARPE-19 Cells thorough Activation of Nrf2 Pathway.Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Therapeutic targeting of the complement system in age-related macular degeneration: a review.Consequences of oxidative stress in age-related macular degeneration.Bowman lecture on the role of inflammation in degenerative disease of the eye.Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.Dry Age-Related Macular Degeneration Pharmacology.CLINICAL ENDPOINTS FOR THE STUDY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION.Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases.Recent developments in age-related macular degeneration: a review.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Oxidative stress and reactive oxygen species: a review of their role in ocular disease.Lipid radicals cause light-induced retinal degeneration.

P2860

Q24202679-38412226-5BE7-480E-B035-037B91C96300 Q24202824-28A97691-EC6B-4811-89CC-9FDCCCF225FB Q24628705-55CB743F-178D-49BB-B4E8-389CC606ED26 Q26774188-FBAA552F-14A2-418E-BDCB-3E80812C2E4B Q26776523-43201E1A-B36C-4C33-92F2-B336F655688F Q26778247-F9B57B41-6D9C-4483-AB26-2262FCD6000C Q26799617-4A4F4866-5B9A-41D5-A432-77C0C443EF8E Q28077181-ABD247FA-F97D-4B73-9A09-808DC9C58D42 Q30565636-44985A79-A719-4034-B6F8-B7850F48587B Q34366170-4DF26637-0CB7-4894-A406-EDFD5E3BC298 Q34378033-7CE45303-46F6-4F9B-AC1C-CA069B4F58DF Q34530196-9E8AE210-D23D-49AD-B192-1F0BA1A9379C Q34645582-E513B683-6304-4447-A560-BEFE6F235583 Q34930298-EFCFD6C4-F894-46FD-B115-1B6F1BB28DFC Q36454668-128B417F-F0FE-4200-8FC2-95D2F7968E2C Q36801990-08B35C1C-7703-41F0-A881-EF7CFB4045C5 Q37253965-FE021B8E-82CE-410E-B95E-4AB858D6778F Q37645117-E291E913-56F0-4C62-A5AE-C61B0E2AEC18 Q37822290-2E3E8332-EEE3-4240-B14A-1A21C3307C0A Q37981256-1FB38CDA-C619-4FF2-85A5-EA7E7DE5DBAE Q38003229-3214CA98-A2FF-4173-8378-7AC3E414F0AC Q38071535-92290249-3BCE-4206-8B93-51A00E7B7B23 Q38653249-A71016F5-ABBF-49AB-AC93-16D384B86D76 Q38653252-BE2CE441-41A3-4824-834C-DDAB8A3C61EB Q38789140-A61148BE-C192-4A2A-AC2B-025AA5523DFE Q38818680-CFD20F44-77D6-4C78-ABEE-425A6ACBFADF Q39039446-C12D99E2-E7F3-44BA-917A-A0783EE648FE Q41532061-AFB35149-76E3-4829-BAB1-A27D67DBCDA2 Q45870879-B630FB47-0892-4F07-BC70-A49E1F8F18BD Q46248374-F31AFDE8-B76B-42D6-A488-14D15E2634DB Q49994873-75C29CC1-0006-4679-9465-1866A906A441

P2860

Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial

http://www.wikidata.org/entity/Q34662112

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Treatment of geographic atroph ...... s of a phase II clinical trial

@ast

Treatment of geographic atroph ...... s of a phase II clinical trial

@en

Treatment of geographic atroph ...... s of a phase II clinical trial

@nl

type

label

Treatment of geographic atroph ...... s of a phase II clinical trial

@ast

Treatment of geographic atroph ...... s of a phase II clinical trial

@en

Treatment of geographic atroph ...... s of a phase II clinical trial

@nl

prefLabel

Treatment of geographic atroph ...... s of a phase II clinical trial

@ast

Treatment of geographic atroph ...... s of a phase II clinical trial

@en

Treatment of geographic atroph ...... s of a phase II clinical trial

@nl

P1433

Q34662112-A99BECA0-6EFB-4415-AFE2-5C6509C50D97

P1476

Q34662112-B5200B1F-0830-44FC-B442-F12CF82F6497

P2093

Q34662112-17B10844-C1A9-45F3-8C1B-0DE4814507C7

Q34662112-2ED42158-D86D-4879-997B-37068E799592

Q34662112-69F60BD9-6D17-4C4B-8CE5-1FF757BCEBDF

Q34662112-9052D731-0DD7-41BE-AA49-F9092F0A56FF

Q34662112-9A4479E2-9FE5-493F-AC39-41569827A83A

Q34662112-BFE3585C-E379-40A8-AD51-B93047C498CD

Q34662112-D3337206-F0EB-4321-BF4F-EE6976C2EC9B

Q34662112-F94C5455-D0CE-4222-8021-57A784944BBD

P2860

Q34662112-0F6DCFB8-6D23-4D35-9067-1DBBF778A73C

Q34662112-197527C9-4CC3-4277-B531-18C0A7CAA2D1

Q34662112-2E5728FD-6BC4-4BD3-AA43-44E008D92E8F

Q34662112-2EFE6323-B22B-46CF-AE13-F55AA0C11398

Q34662112-3E0BF713-78F4-4BC7-936F-3D80BDFE54E9

Q34662112-4F64EB5E-7585-48B5-922E-67A8F8CA2404

Q34662112-54CD1CB4-51CF-47F4-A9F3-80D5AF3E2EF4

Q34662112-5696D776-A5C2-45AC-8297-5D4761DA319E

Q34662112-59826AC0-296A-44E2-BC48-EA455265A214

Q34662112-5A96DF55-F5DE-43E4-83C3-A06FA4360398

P304

Q34662112-0FF4AD00-3DBC-44F6-962D-191AEFE46264

P31

Q34662112-D793CB28-E592-40B8-B3DD-16797140EBA7

P356

Q34662112-05E7D26C-16AA-4AD4-95ED-F6652795EEA4

P407

Q34662112-4F466D41-F9E0-4A36-8A92-D487DB7E90F2

P433

Q34662112-FED3F769-ADD7-4B76-AE5C-30BB4FBC08B7

P478

Q34662112-65CAC2F8-33A2-4A8E-B676-FE02AE0215AC

P50

Q34662112-53FA6EAE-B260-43F0-8048-D026BAE4E53B

Q34662112-B9997C68-FD65-4693-94E7-2EC2202DA64B

P577

Q34662112-D24EECDA-D0E2-46BC-B789-08C5AB10ACE2

P5875

Q34662112-205D5FCA-93B5-48EE-943A-1AA75F8C828F

P698

Q34662112-3D380760-EDCC-4AF7-AF27-40C453D52012

P921

Q34662112-B17A80A1-9ADE-48FF-BF3C-3DEB97FB86C0

P932

Q34662112-CC62629C-A6B9-4B88-B864-D831CEB22231

P356

P1433

Investigative Ophthalmology & Visual Science

P1476

Treatment of geographic atroph ...... s of a phase II clinical trial

@en

P2093

Catherine B Meyerle

http://www.w3.org/2001/XMLSchema#string

Denise Cunningham

http://www.w3.org/2001/XMLSchema#string

Frederick L Ferris

http://www.w3.org/2001/XMLSchema#string

Keri Hammel

http://www.w3.org/2001/XMLSchema#string

Molly Harrington

http://www.w3.org/2001/XMLSchema#string

Srinivas R Sadda

http://www.w3.org/2001/XMLSchema#string

Wai T Wong

http://www.w3.org/2001/XMLSchema#string

Waynekid Kam

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9

Aging: a theory based on free radical and radiation chemistry

Analysis of digital scanning laser ophthalmoscopy fundus autofluorescence images of geographic atrophy in advanced age-related macular degeneration.

Improvement of visual acuity over time in patients with bilateral geographic atrophy from age-related macular degeneration.

Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study.

Modelling the natural history of geographic atrophy in patients with age-related macular degeneration.

Issues in quantifying atrophic macular disease using retinal autofluorescence.

High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration.

Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice.

Comparison of fundus autofluorescence of age-related macular degeneration between a fundus camera and a confocal scanning laser ophthalmoscope.

P304

6131-6139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1167/IOVS.10-5637

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

Catherine Cukras

P577

2010-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44698335

http://www.w3.org/2001/XMLSchema#string

P698

20574018

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3055748

http://www.w3.org/2001/XMLSchema#string